NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Seeking Alpha / 45 minutes from now 2 Views
Comments